<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="906">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817293</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH_2021_01</org_study_id>
    <nct_id>NCT04817293</nct_id>
  </id_info>
  <brief_title>Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With COVID-19 Infection in the Hauts de France Region</brief_title>
  <acronym>COCO_Vi_LATE</acronym>
  <official_title>Coordinated Research on Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With SARS-COV-2 Infection: a Transversal Study in Town in the Hauts de France Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tourcoing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several publications document the occurrence of prolonged or late-onset symptoms beyond 3&#xD;
      weeks after the first clinical manifestations of SARS-COV2 infection. These manifestations&#xD;
      may be related to thromboembolic or inflammatory events or other mechanisms that are not yet&#xD;
      well understood. The psychosomatic origin secondary to psychiatric disorders prior to the&#xD;
      infection or in reaction to it is also to be evoked. The identification of the clinical&#xD;
      manifestations observed, and their clinical and paraclinical evolution are essential to&#xD;
      better understand the natural evolution of COVID-19, to specify the physiopathological&#xD;
      mechanisms and to identify potential avenues of management for the patients. In addition, the&#xD;
      impact of COVID-19 infection on primary care visits is not known. In general practice, these&#xD;
      patients benefit from explorations and even diagnoses that may explain the persistence of&#xD;
      symptoms (autoimmune diseases, thrombosis, somatoform disorders, hyperventilation syndrome,&#xD;
      etc.).&#xD;
&#xD;
      The objective of the COCO_Vi_LATE project is to carry out a cross-sectional study of patients&#xD;
      presenting persistent and/or recurrent symptoms after an infection with SARS-COV-2 who will&#xD;
      be compared to individuals with a short form of infection with COVID-19&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the reasons for consultation between patients with a history of Covid 19 and those who have not been infected with SARS-CoV-2.</measure>
    <time_frame>At day 1</time_frame>
    <description>The judgement criterion will be the reasons for consultation standardized with the CISP-2 classification (International Classification of Primary Care).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Assess the presence of somatoform disorders between COVID-19 and non-COVID-19 patients.</measure>
    <time_frame>At day 1</time_frame>
    <description>The assessment will be done using the international SSD-12 scale (Symptom Disorder-B Criteria Scale). The SSD-12 is composed of 12 items; each of the three psychological subcriteria is measured by four items (cognitive aspects; affective aspects; behavioral aspects).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the quality of life of COVID-19 patients with that of non-COVID-19 patients.</measure>
    <time_frame>At day 1</time_frame>
    <description>The EQ-5D-5L scale is composed of - the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Each level corresponds to 1-digit number expressing the level selected for that dimension.The EQ VAS corresponds to a 20 cm vertical, visual analogue scale raging from 'the best health you can imagine' to 'the worst health you can imagine'.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>COVID-19 positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 negative</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaire SSD-12 and EQ5D5L</description>
    <arm_group_label>COVID-19 negative</arm_group_label>
    <arm_group_label>COVID-19 positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical consultation</intervention_name>
    <description>Medical consultation during the visit with data collection</description>
    <arm_group_label>COVID-19 negative</arm_group_label>
    <arm_group_label>COVID-19 positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        he study population consisted of patients with COVID-19 infection and patients without&#xD;
        COVID-19 infection consulting their general practitioner during the study inclusion period.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A- For COVID cases:&#xD;
&#xD;
          1. Consultation in a city doctor's office&#xD;
&#xD;
          2. Positive SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology&#xD;
&#xD;
          3. Patient symptomatic or not&#xD;
&#xD;
        Definition of symptomatic :&#xD;
&#xD;
          1. Anosmia&#xD;
&#xD;
          2. OR CT scan suggestive of COVID 19&#xD;
&#xD;
          3. OR â‰¥ 2 symptoms contemporaneous with virologic sampling among: asthenia, cough,&#xD;
             dyspnea, fever, myalgias, dysgeusia, diarrhea AND not present previously at diagnosis&#xD;
&#xD;
        B-. For NON COVID cases:&#xD;
&#xD;
          1. Consultation in a city doctor's office&#xD;
&#xD;
          2. No known COVID+ serology&#xD;
&#xD;
          3. No known RT- PCR SARS-CoV-2&#xD;
&#xD;
          4. No clinical suspicion of COVID-19 infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Minor patient&#xD;
&#xD;
          2. Refusal to participate&#xD;
&#xD;
          3. Patient under protection&#xD;
&#xD;
          4. Patient requiring hospitalization for COVID-19 (excluding non-emergency&#xD;
             hospitalization)&#xD;
&#xD;
          5. Patient consulted for the following reason only: treatment monitoring, treatment&#xD;
             renewal or certificate, hospital discharge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier ROBINEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Tourcoing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie PANAGET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier ROBINEAU, MD</last_name>
    <phone>0320694949</phone>
    <email>orobineau@ch-tourcoing.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solange TREHOUX, PhD</last_name>
    <phone>0320694280</phone>
    <email>strehoux@ch-tourcoing.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

